HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Tests Show CBD Levels In Some Supplements Don't Match Labeling

Executive Summary

Seven of 10 CBD-containing supplement products tested in a lab did not contain the levels of CBD advertised on the label, says hemp, CBD and natural health product information publisher Remedy Reviews. Most products also were found to contain heavy metals.

You may also be interested in...



US FDA Continues Cannabinoid Analysis Required In FY2021 Budget

FDA is testing cannabidiol and other cannabinoids for whether labeled amounts match what’s in a product, says CFSAN Deputy Director Doug Stearn. The work is supported with $5m provided in the agency’s FY21 appropriation.

Pocono Organics Sprouts Full-Spectrum Cannabinoids Line Grown In Regenerative Farming

Pennsylvania firm's CBD line is only one with the Rodale Institute’s logo to indicate the high standards and responsible farming practices used to make the items. The line includes artisanal, small-batch tinctures, creams, salve sticks, lip balms, massage oil and bath bombs.

Digital Citizens Study Finds Many CBD Products Are Placebos And Most Are Inaccurately Labeled

Digital Citizens Alliance found an average 30% discrepancy between labeled and actual CBD amounts in nearly 60 products. The group says more than half the products tested contained CBD levels 20% higher or lower than labeled, which is particularly problematic since nearly half US consumers use the products as alternatives to Rx drugs.

Related Content

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

RS149490

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel